ABUS

Arbutus Biopharma Corporation (ABUS) | Rumor.io

Arbutus Biopharma

ABUS

Attention (50-day avg)0%

Attention rank (50-day avg)#975

Bullish sentiment (50-day avg)78%

Price to earnings ratio6.14

Market capitalization962.8M

Earnings per share0.79

Dividend yield (TTM)—

Revenue (annual)14.1M

Net income (annual)-33.5M

Social

What share of all stock conversation is about ABUS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 23

$ABUS has been trading below its range of $5-$5.75, with some directors participating in the odd lot tender offer.
The Dutch auction has been criticized for allowing shares to be sold below $5, potentially benefiting only large institutions.
The stock has experienced a selloff, with prices reaching $4.77 and $4.85 in the final minutes of trading, and the arbitrage algos are buying in.

Generated by AI

Sentiment

Of the messages about ABUS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	50% -50	79.75% +2.12	73.71% -3.49
Bearish	—	50% new	20.25% -2.12	26.29% +3.49

Bullish· Aug 21

The company's stock price has seen significant volume, with today's volume on track to be the biggest in 3 years, indicating a strong uptrend.
Institutions and large shareholders have been accumulating shares for 2-3 years, suggesting that the company's value has been underestimated and that long-term investors will soon be rewarded.
The company's LNP technology has shown great promise for new products and revenues, including a potential cure for Hepatitis B and a fast-tracked pipeline for cancer drug development.

Bearish· Apr 15

The company's recent court cases and Hepatitis B news may be contributing to the decline in stock price.
The stock's price movement is being manipulated by short sellers and market makers, who are controlling the price.
The analyst's lowered target price to $5.50 suggests a bearish outlook for the company's future performance.

Generated by AI

Topics

Of the messages about ABUS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	55.1%	43.37%
Controversies	—	0%	18.37%	45.21%
Technical Analysis	—	0%	2.04%	5.68%
Earnings	—	0%	6.12%	2.3%
Analysts	—	0%	18.37%	2.01%
Macro	—	0%	0%	1.43%

Earnings· Aug 7

Arbutus Biopharma Corporation (ABUS) reported Q2 EPS of ($0.25), $0.01 worse than the analyst estimate of ($0.24).
Revenue for the quarter came in at $1.51 million versus the consensus estimate of $1.74 million.
ABUS's stock price was down around 14% after the earnings release, despite a 45.65% increase in earnings per share over the past year.

Analysts· Jul 27

Analyst Liisa Bayko from JMP Securities rated ABUS with a Buy and 5-star rating.
B. Riley raised ABUS's price target to $8.00, citing the company's contributions to the COVID-19 R&D consortium and its progress in the Phase I dose escalation study of AB-729.
Analysts are highly confident in ABUS, with a 87% buy consensus and a median 12-month price forecast of $5.00, representing a -2.72% decrease from the last price.

Announcements· Mar 4

Arbutus Biopharma Corporation (ABUS) has reached a $950M settlement with Moderna over the licensing of LNP delivery technology, with potential for an additional $1.3B payment.
The settlement validates Arbutus' IP and creates a massive acquisition target, with Pfizer potentially acquiring ABUS to strengthen its strategic position in relation to the UK Court of Appeal ruling.
The deal opens up new opportunities for Arbutus, including potential partnerships and licensing agreements, with the company emerging as a recognized IP holder within the mRNA ecosystem.

Controversies· Mar 4

Arbutus Biopharma Corporation (ABUS) is involved in a high-profile patent infringement case against Moderna, with a reported $2.2 billion settlement.
The settlement is seen as a significant arbitrage opportunity, with some analysts suggesting that the stock price should be higher given the potential for further settlements with Pfizer.
The controversy surrounding ABUS's aggressive pursuit of patent infringement claims may harm the company's reputation within the industry, potentially stymying its growth in the near future.

Technical Analysis· Dec 9

ABUS has broken out of a symmetrical triangle and is targeting $5, with a high probability of success.
The stock has held up well during the recent market downturn and has shown strong volume and action, indicating a potential breakout.
ABUS has moved above its 50-day Moving Average and is in a bullish trend, with a potential target of $6.5 if it closes above $4.5.

Generated by AI

Community

Of the messages about ABUS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	78.48%	81.41%	88.04%
Newcomers	—	21.52%	18.59%	11.96%

Regulars· Sep 23

The Dutch auction for Arbutus Biopharma (ABUS) shares has been criticized for being reserved for long-term shares only, with some participants expressing concerns that it has been a "disaster" for regular investors.
There is speculation about a potential bounce in the stock price, with some participants expecting a rebound off the 50-day moving average at $4.80, while others are skeptical and predict a further decline.
The arbitrage algos are actively buying and selling ABUS shares, while the passive algos are following the market and selling, with some participants expressing frustration with the stock's performance and comparing it unfavorably to a team like the Cleveland Browns.

Newcomers· Aug 21

The company, Arbutus Biopharma, plans to repurchase up to $230 million of its own shares through a modified Dutch auction tender offer, with a price range of $5.00 to $5.75 per share.
The buyback is funded by a patent settlement windfall, and the company expects to start the offer around August 24 and expire around September 29, 2026.
The repurchase plan has sparked debate among investors, with some questioning the timing and others seeing it as a potential opportunity for long-term holders, with the stock currently trading at around $5.22.

Generated by AI

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

4d agoBenzinga

Arbutus launches $230 million share buyback tender offer

1mo agoInvesting.com

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the commencement of a modified “Dutch Auction” tender offer to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”) at a price of not less than US$5.00 and not more than US $5.75 per Share, less any applicable withholding taxes and without inter

1mo agoYahoo Finance

Arbutus Biopharma Launches $230 Million Tender Offer for Common Shares

Arbutus Biopharma (ABUS) has commenced a tender offer to purchase for cancellation its common shares

1mo agofinance.yahoo.com

Why is Arbutus Biopharma stock surging today?

1mo agoInvesting.com

Arbutus Gains on $230m Buyback Using Moderna Settlement Proceeds

1mo agoBloomberg.com

Also Discussed

Investors talking about ABUS also mention

#	Name	Attention
1	Roivant Sciences Ltd.ROIV	0%new
2	Alnylam Pharmaceuticals, Inc.ALNY	0%0
3	Arrowhead Pharmaceuticals, Inc.ARWR	0%+0
4	Moderna Inc.MRNA	0.1%+0.03
5	Barinthus Biotherapeutics plcBRNS	0%new
6	Lakeland Industries, Inc.LAKE	0%0
7	BioNTech SEBNTX	0%+0
8	Ionis Pharmaceuticals, Inc.IONS	0%new
9	LUMO - Lumos Pharma, Inc.	——
10	Alpha Pro Tech, Ltd.APT	0%new

Arbutus Biopharma Corporation

Healthcare
Biotechnology

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, with particular emphasis on chronic hepatitis B virus infection. Arbutus Biopharma Corporation is developing imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNA interference therapeutic, and AB-101, an oral PD-L1 inhibitor, both designed to target different aspects of HBV biology and immune response. The company’s work centers on advancing virology-based therapies that may contribute to improved treatment options for patients living with chronic hepatitis B. Arbutus Biopharma Corporation operates within the broader biotechnology sector, where its current programs, proprietary drug candidates, and infectious-disease focus position it as a specialized developer of novel therapeutics.

Website

Location

701 Veterans Circle

Warminster, PA, 18974

United States

Social

What share of all stock conversation is about ABUS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 23

$ABUS has been trading below its range of $5-$5.75, with some directors participating in the odd lot tender offer.
The Dutch auction has been criticized for allowing shares to be sold below $5, potentially benefiting only large institutions.
The stock has experienced a selloff, with prices reaching $4.77 and $4.85 in the final minutes of trading, and the arbitrage algos are buying in.

Generated by AI

Sentiment

Of the messages about ABUS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	50% -50	79.75% +2.12	73.71% -3.49
Bearish	—	50% new	20.25% -2.12	26.29% +3.49

Bullish· Aug 21

The company's stock price has seen significant volume, with today's volume on track to be the biggest in 3 years, indicating a strong uptrend.
Institutions and large shareholders have been accumulating shares for 2-3 years, suggesting that the company's value has been underestimated and that long-term investors will soon be rewarded.
The company's LNP technology has shown great promise for new products and revenues, including a potential cure for Hepatitis B and a fast-tracked pipeline for cancer drug development.

Bearish· Apr 15

The company's recent court cases and Hepatitis B news may be contributing to the decline in stock price.
The stock's price movement is being manipulated by short sellers and market makers, who are controlling the price.
The analyst's lowered target price to $5.50 suggests a bearish outlook for the company's future performance.

Generated by AI

Topics

Of the messages about ABUS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	55.1%	43.37%
Controversies	—	0%	18.37%	45.21%
Technical Analysis	—	0%	2.04%	5.68%
Earnings	—	0%	6.12%	2.3%
Analysts	—	0%	18.37%	2.01%
Macro	—	0%	0%	1.43%

Earnings· Aug 7

Arbutus Biopharma Corporation (ABUS) reported Q2 EPS of ($0.25), $0.01 worse than the analyst estimate of ($0.24).
Revenue for the quarter came in at $1.51 million versus the consensus estimate of $1.74 million.
ABUS's stock price was down around 14% after the earnings release, despite a 45.65% increase in earnings per share over the past year.

Analysts· Jul 27

Analyst Liisa Bayko from JMP Securities rated ABUS with a Buy and 5-star rating.
B. Riley raised ABUS's price target to $8.00, citing the company's contributions to the COVID-19 R&D consortium and its progress in the Phase I dose escalation study of AB-729.
Analysts are highly confident in ABUS, with a 87% buy consensus and a median 12-month price forecast of $5.00, representing a -2.72% decrease from the last price.

Announcements· Mar 4

Arbutus Biopharma Corporation (ABUS) has reached a $950M settlement with Moderna over the licensing of LNP delivery technology, with potential for an additional $1.3B payment.
The settlement validates Arbutus' IP and creates a massive acquisition target, with Pfizer potentially acquiring ABUS to strengthen its strategic position in relation to the UK Court of Appeal ruling.
The deal opens up new opportunities for Arbutus, including potential partnerships and licensing agreements, with the company emerging as a recognized IP holder within the mRNA ecosystem.

Controversies· Mar 4

Arbutus Biopharma Corporation (ABUS) is involved in a high-profile patent infringement case against Moderna, with a reported $2.2 billion settlement.
The settlement is seen as a significant arbitrage opportunity, with some analysts suggesting that the stock price should be higher given the potential for further settlements with Pfizer.
The controversy surrounding ABUS's aggressive pursuit of patent infringement claims may harm the company's reputation within the industry, potentially stymying its growth in the near future.

Technical Analysis· Dec 9

ABUS has broken out of a symmetrical triangle and is targeting $5, with a high probability of success.
The stock has held up well during the recent market downturn and has shown strong volume and action, indicating a potential breakout.
ABUS has moved above its 50-day Moving Average and is in a bullish trend, with a potential target of $6.5 if it closes above $4.5.

Generated by AI

Community

Of the messages about ABUS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	78.48%	81.41%	88.04%
Newcomers	—	21.52%	18.59%	11.96%

Regulars· Sep 23

The Dutch auction for Arbutus Biopharma (ABUS) shares has been criticized for being reserved for long-term shares only, with some participants expressing concerns that it has been a "disaster" for regular investors.
There is speculation about a potential bounce in the stock price, with some participants expecting a rebound off the 50-day moving average at $4.80, while others are skeptical and predict a further decline.
The arbitrage algos are actively buying and selling ABUS shares, while the passive algos are following the market and selling, with some participants expressing frustration with the stock's performance and comparing it unfavorably to a team like the Cleveland Browns.

Newcomers· Aug 21

The company, Arbutus Biopharma, plans to repurchase up to $230 million of its own shares through a modified Dutch auction tender offer, with a price range of $5.00 to $5.75 per share.
The buyback is funded by a patent settlement windfall, and the company expects to start the offer around August 24 and expire around September 29, 2026.
The repurchase plan has sparked debate among investors, with some questioning the timing and others seeing it as a potential opportunity for long-term holders, with the stock currently trading at around $5.22.

Generated by AI

Arbutus Biopharma

Social

Sep 23

Bullish· Aug 21

Bearish· Apr 15

Earnings· Aug 7

Analysts· Jul 27

Announcements· Mar 4

Controversies· Mar 4

Technical Analysis· Dec 9

Regulars· Sep 23

Newcomers· Aug 21

10 Health Care Stocks With Whale Alerts In Today’s Session - Arbutus Biopharma (NASDAQ:ABUS), Novo Nordis

Arbutus launches $230 million share buyback tender offer

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

Arbutus Biopharma Launches $230 Million Tender Offer for Common Shares

Why is Arbutus Biopharma stock surging today?

Arbutus Gains on $230m Buyback Using Moderna Settlement Proceeds

Also Discussed

Arbutus Biopharma Corporation

Company Information

Location

10 Health Care Stocks With Whale Alerts In Today’s Session - Arbutus Biopharma (NASDAQ:ABUS), Novo Nordis

Arbutus launches $230 million share buyback tender offer

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

Arbutus Biopharma Launches $230 Million Tender Offer for Common Shares

Why is Arbutus Biopharma stock surging today?

Arbutus Gains on $230m Buyback Using Moderna Settlement Proceeds

Also Discussed

Social

Sep 23

Bullish· Aug 21

Bearish· Apr 15

Earnings· Aug 7

Analysts· Jul 27

Announcements· Mar 4

Controversies· Mar 4

Technical Analysis· Dec 9

Regulars· Sep 23

Newcomers· Aug 21